Physiologically-based modeling and interspecies prediction of paclitaxel pharmacokinetics.

Abstract:

:The objective was to develop a physiologically-based pharmacokinetic (PBPK) model to characterize the whole-body disposition of paclitaxel (formulated in Cremophor EL and ethanol-Taxol®) in mice and to evaluate the utility of this model for predicting pharmacokinetics in other species. Published studies that reported paclitaxel plasma and tissue concentration-time data following single intravenous bolus administration of Taxol® to mice were used; and the PBPK model included plasma, liver, lungs, kidneys, spleen, heart, gastrointestinal tract, and remainder compartments. The final model resulted in a good description of the experimental plasma and tissues data in mice, where all tissues were represented by a single compartment, except the remainder that included two sub-compartments. The predictive performance of the PBPK model was assessed by evaluating its utility in predicting pharmacokinetics of paclitaxel in rats and humans. The relationship between species body weights (mice, rats, rabbits, and humans) and plasma clearance was determined by power-based regression, and resulting allometric exponent was 0.86. The model demonstrated reasonable predictions of plasma and tissue paclitaxel concentration-time profiles in rats and plasma profiles in humans. The proposed PBPK model represents an important basis that can be further utilized for characterization of novel formulations of paclitaxel.

authors

Zang X,Kagan L

doi

10.1007/s10928-018-9586-9

subject

Has Abstract

pub_date

2018-08-01 00:00:00

pages

577-592

issue

4

eissn

1567-567X

issn

1573-8744

pii

10.1007/s10928-018-9586-9

journal_volume

45

pub_type

杂志文章
  • Robust population pharmacokinetic experiment design.

    abstract::The population approach to estimating mixed effects model parameters of interest in pharmacokinetic (PK) studies has been demonstrated to be an effective method in quantifying relevant population drug properties. The information available for each individual is usually sparse. As such, care should be taken to ensure t...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-2102-z

    authors: Dodds MG,Hooker AC,Vicini P

    更新日期:2005-02-01 00:00:00

  • Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations.

    abstract::The utilisation of physiologically-based pharmacokinetic models for the analysis of population data is an approach with progressively increasing impact. However, as we move from empirical to complex mechanistic model structures, incorporation of stochastic variability in model parameters can be challenging due to the ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-015-9418-0

    authors: Tsamandouras N,Wendling T,Rostami-Hodjegan A,Galetin A,Aarons L

    更新日期:2015-08-01 00:00:00

  • A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients.

    abstract::Long term therapy with antiretroviral agents in HIV-infected patients often result in failure to suppress the virus load. Imperfect adherence to prescribed antiviral drugs is an important factor explaining the resurgence of virus. A better understanding of the factors responsible for the virological failure is importa...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9022-4

    authors: Labbé L,Verotta D

    更新日期:2006-08-01 00:00:00

  • A Bayesian population analysis of the development of type 2 diabetes in the offspring of diabetic parents.

    abstract::Disease progression of type 2 diabetes (T2D) has received considerable attention, but little is known about the disease development of T2D. The purposes of this study were to identify disease development variables (DDV) for development of T2D and to compare corresponding models for disease development. All subjects in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-011-9208-2

    authors: Lin CW,Warram JH,Veng-Pedersen P

    更新日期:2011-10-01 00:00:00

  • Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

    abstract::In the present pharmacokinetic/pharmacodynamic (PK/PD) evaluation, cortisol, total lymphocytes, and lymphocyte subpopulations were monitored following single oral doses of two oral formulations of 3 mg budesonide (BUD) (Dosage Forms A and B) in order to assess the differential effects that BUD may have on cortisol sup...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9013-5

    authors: Stark JG,Werner S,Homrighausen S,Tang Y,Krieg M,Derendorf H,Moellmann H,Hochhaus G

    更新日期:2006-08-01 00:00:00

  • A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

    abstract::Effective long-term treatment of Type 2 Diabetes Mellitus (T2DM) implies modification of the disease processes that cause this progressive disorder. This paper proposes a mechanism-based approach to disease progression modeling of T2DM that aims to provide the ability to describe and quantify the effects of treatment ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-006-9008-2

    authors: de Winter W,DeJongh J,Post T,Ploeger B,Urquhart R,Moules I,Eckland D,Danhof M

    更新日期:2006-06-01 00:00:00

  • Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria.

    abstract::The study aimed to characterize the population pharmacokinetics of amodiaquine (AQ) and its major metabolite N-desethylamodiaquine (N-DEAQ), and to assess the correlation between exposure to N-DEAQ and treatment outcome. Blood samples from children in two studies in Zanzibar and one in Papua New Guinea were included i...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9064-2

    authors: Hietala SF,Bhattarai A,Msellem M,Röshammar D,Ali AS,Strömberg J,Hombhanje FW,Kaneko A,Björkman A,Ashton M

    更新日期:2007-10-01 00:00:00

  • A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects.

    abstract::HbA1c is the most commonly used biomarker for the adequacy of glycemic management in diabetic patients and a surrogate endpoint for anti-diabetic drug approval. In spite of an empirical description for the relationship between average glucose (AG) and HbA1c concentrations, obtained from the A1c-derived average glucose...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9289-6

    authors: Lledó-García R,Mazer NA,Karlsson MO

    更新日期:2013-04-01 00:00:00

  • Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.

    abstract::The emerging discipline of mathematical pharmacology occupies the space between advanced pharmacometrics and systems biology. A characteristic feature of the approach is application of advance mathematical methods to study the behavior of biological systems as described by mathematical (most often differential) equati...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9546-9

    authors: Gibiansky L,Gibiansky E

    更新日期:2018-02-01 00:00:00

  • A reduction in between subject variability is not mandatory for selecting a new covariate.

    abstract::Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for heterogeneity termed betwe...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9256-2

    authors: Lagishetty CV,Vajjah P,Duffull SB

    更新日期:2012-08-01 00:00:00

  • A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

    abstract::The pharmacokinetics of cyclosporin (CsA) are unusual because of several heterogeneous features which include the presence of more than one conformer, considerable accumulation in erythrocytes and lipoproteins, extensive plasma protein binding, distribution into deep tissues, biliary secretion and hepatic clearance in...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1012295014352

    authors: Claret L,Iliadis A,Macheras P

    更新日期:2001-10-01 00:00:00

  • Assessing the dynamics of nuclear glucocorticoid-receptor complex: adding flexibility to gene expression modeling.

    abstract::A retrospective analysis was performed to modify our fourth-generation pharmacodynamic model for glucocorticoid receptor (GR) dynamics with incorporation of more physiological features. This modified model was developed by integrating previously reported free cytosolic GR and GR mRNA data following single (10, 50 mg/k...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-007-9049-1

    authors: Hazra A,DuBois DC,Almon RR,Jusko WJ

    更新日期:2007-06-01 00:00:00

  • Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers.

    abstract::The pharmacokinetic-pharmacodynamic (PK-PD) relationship of the granulopoietic effects of Filgrastim in healthy volunteers was characterized via a population approach. Healthy male volunteers were enrolled into a four-way crossover clinical trial. Subjects received four single doses of Filgrastim (375 and 750 microgra...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011534529622

    authors: Wang B,Ludden TM,Cheung EN,Schwab GG,Roskos LK

    更新日期:2001-08-01 00:00:00

  • Modeling cancer-immune responses to therapy.

    abstract::Cancer therapies that harness the actions of the immune response, such as targeted monoclonal antibody treatments and therapeutic vaccines, are relatively new and promising in the landscape of cancer treatment options. Mathematical modeling and simulation of immune-modifying therapies can help to offset the costs of d...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-014-9386-9

    authors: dePillis LG,Eladdadi A,Radunskaya AE

    更新日期:2014-10-01 00:00:00

  • Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study.

    abstract::There are situations in drug development where one may wish to reduce the dimensionality and complexity of whole body physiologically based pharmacokinetic models. A technique for formal reduction of such models, based on global sensitivity analysis, is suggested. Using this approach mean and variance of tissue(s) and...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0004-8

    authors: Gueorguieva I,Nestorov IA,Rowland M

    更新日期:2006-02-01 00:00:00

  • Benchmarking renin suppression and blood pressure reduction of direct renin inhibitor imarikiren through quantitative systems pharmacology modeling.

    abstract::Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII). There is a strong non-linear feedback from AT1-bound AngII on renin secretion. Since AT...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9612-y

    authors: Gebremichael Y,Lahu G,Vakilynejad M,Hallow KM

    更新日期:2019-02-01 00:00:00

  • Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis.

    abstract::Changes in the reticulocyte subtype distribution (high, medium and low reticulocytes count (HR, MR, LR)) measured by flow cytometry following phlebotomy-induced stress erythropoiesis (abruptly dropping hemoglobin to 3-4 g/dl over 4-5 hr) and the pharmacodynamic (PD) relationship to the stimulated erythropoietin (EPO) ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-005-0009-3

    authors: Al-Huniti NH,Widness JA,Schmidt RL,Veng-Pedersen P

    更新日期:2005-08-01 00:00:00

  • Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

    abstract::We propose an efficient algorithm for screening covariates in population model building using Wald's approximation to the likelihood ratio test (LRT) statistic in conjunction with Schwarz's Bayesian criterion. The algorithm can be applied to a full model fit of k covariate parameters to calculate the approximate LRT f...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1023/a:1011579109640

    authors: Kowalski KG,Hutmacher MM

    更新日期:2001-06-01 00:00:00

  • Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.

    abstract::Bootstrap methods are used in many disciplines to estimate the uncertainty of parameters, including multi-level or linear mixed-effects models. Residual-based bootstrap methods which resample both random effects and residuals are an alternative approach to case bootstrap, which resamples the individuals. Most PKPD app...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9343-z

    authors: Thai HT,Mentré F,Holford NH,Veyrat-Follet C,Comets E

    更新日期:2014-02-01 00:00:00

  • Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

    abstract::This study was designed to investigate ethnic differences in the pharmacokinetics (PKs) of moxifloxacin and its metabolites, M1 (sulfo conjugate) and M2 (acyl-glucuronate), among Japanese, Chinese, and Korean populations, following oral administration. We used a population PK modeling approach using data from a clinic...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9556-7

    authors: Kaneko M,Aoyama T,Ishida Y,Miyamoto A,Saito Y,Tohkin M,Kawai S,Matsumoto Y

    更新日期:2018-04-01 00:00:00

  • The effect of using a robust optimality criterion in model based adaptive optimization.

    abstract::Optimizing designs using robust (global) optimality criteria has been shown to be a more flexible approach compared to using local optimality criteria. Additionally, model based adaptive optimal design (MBAOD) may be less sensitive to misspecification in the prior information available at the design stage. In this wor...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-017-9521-5

    authors: Strömberg EA,Hooker AC

    更新日期:2017-08-01 00:00:00

  • General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

    abstract::Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characteriz...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1014414520282

    authors: Mager DE,Jusko WJ

    更新日期:2001-12-01 00:00:00

  • Is mixed effects modeling or naïve pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data?

    abstract::The purpose of this study was to evaluate whether mixed effects modeling (MEM) performs better than either noncompartmental or compartmental naïve pooled data (NPD) analysis for the interpretation of single sample per subject pharmacokinetic (PK) data. Using PK parameters determined during a toxicokinetic study in rat...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1023/a:1011507100493

    authors: Hing JP,Woolfrey SG,Greenslade D,Wright PM

    更新日期:2001-04-01 00:00:00

  • Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling.

    abstract::Cell-level kinetic models for therapeutically relevant processes increasingly benefit the early stages of drug development. Later stages of the drug development processes, however, rely on pharmacokinetic compartment models while cell-level dynamics are typically neglected. We here present a systematic approach to int...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-012-9243-7

    authors: Krippendorff BF,Oyarzún DA,Huisinga W

    更新日期:2012-04-01 00:00:00

  • Structural identifiability and sensitivity.

    abstract::Ordinary differential equation models often contain a large number of parameters that must be determined from measurements by estimation procedure. For an estimation to be successful there must be a unique set of parameters that can have produced the measured data. This is not the case if a model is not structurally i...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-019-09624-9

    authors: Iliadis A

    更新日期:2019-04-01 00:00:00

  • A quantitative systems pharmacological approach identified activation of JNK signaling pathway as a promising treatment strategy for refractory HER2 positive breast cancer.

    abstract::HER2-positive breast cancer (BC) is a rapidly growing and aggressive BC subtype that predominantly affects younger women. Despite improvements in patient outcomes with anti-HER2 therapy, primary and/or acquired resistance remain a major clinical challenge. Here, we sought to use a quantitative systems pharmacological ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-020-09732-x

    authors: Franco YL,Ramakrishnan V,Vaidya TR,Mody H,Perez L,Ait-Oudhia S

    更新日期:2021-01-03 00:00:00

  • Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

    abstract::In this work a model for analyzing categorical data is presented; the differential odds model. Unlike the commonly used proportional odds model, this model does not assume that a covariate affects all categories equally on the log odds scale. The differential odds model was compared to the proportional odds model, by ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-008-9098-0

    authors: Kjellsson MC,Zingmark PH,Jonsson EN,Karlsson MO

    更新日期:2008-10-01 00:00:00

  • Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

    abstract::The physiologically based pharmacokinetic (PBPK) models allow for predictive assessment of variability in population of interest. One of the future application of PBPK modeling is in the field of precision dosing and personalized medicine. The aim of the study was to develop PBPK model for amitriptyline given orally, ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-018-9597-6

    authors: Tylutki Z,Mendyk A,Polak S

    更新日期:2018-10-01 00:00:00

  • Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

    abstract:AIM:Chemotherapy with indisulam causes myelosuppression. This study aimed to evaluate the influence of patient-related covariates on pharmacokinetics and pharmacodynamics, to identify patients at risk for severe myelosuppression and to develop a dosing algorithm for treatment optimization. METHODS:Pharmacokinetic and ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-009-9111-2

    authors: Zandvliet AS,Schellens JH,Copalu W,Beijnen JH,Huitema AD

    更新日期:2009-02-01 00:00:00

  • Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

    abstract::Previously, we developed a feedback model to describe the tolerance and oscillatory rebound of non-esterified fatty acid (NEFA) plasma concentrations in male Sprague Dawley rats after intravenous infusions of nicotinic acid (NiAc). This study challenges that model, using the following regimens of intravenous and oral ...

    journal_title:Journal of pharmacokinetics and pharmacodynamics

    pub_type: 杂志文章

    doi:10.1007/s10928-013-9325-1

    authors: Ahlström C,Peletier LA,Gabrielsson J

    更新日期:2013-08-01 00:00:00